The landscape of vascular access is evolving rapidly, driven by new therapies, increasingly complex patient needs, and an ever\u2011stronger focus on safety and consistency. As clinicians strive to balance therapeutic effectiveness with minimising harm, high\u2011quality guidance becomes essential. At the end of 2025, two major publications answered that call: the Association of Anaesthetists\u2019 Safe Vascular Access Guidelines 2025 and the Michigan Appropriateness Guide for Intravenous Catheters in Adult Patients with Cancer (MAGIC\u2011ONC).<\/p>\n\n\n\n
These documents arrive at a pivotal moment. They bring together the latest scientific evidence with expert consensus to support clearer, more confident decision\u2011making, particularly in oncology, where vascular access is both indispensable and high-risk. MAGIC\u2011ONC alone assessed 1,422 clinical scenarios, providing one of the most comprehensive, detailed frameworks ever developed for device selection, insertion, maintenance, and complication management in adult cancer patients.<\/p>\n\n\n\n
The summary below focuses on the key insights and recommendations from MAGIC\u2011ONC, giving you a practical, clinician\u2011friendly overview of what has changed, what\u2019s new, and what this means for safe vascular access practice moving forward.<\/p>\n\n\n\n
Vascular access is essential for diagnostics, chemotherapy, blood products, antimicrobials, nutrition, and supportive treatments. Yet complications such as infection and thrombosis remain common and avoidable.
MAGIC\u2011ONC provides clinicians with clear, evidence\u2011based device selection principles aimed at:<\/p>\n\n\n\n
MAGIC\u2011ONC reviewed 1,422 real\u2011world clinical scenarios to understand how cancer type, urgency of treatment and expected dwell time influence vascular access decisions. Each scenario and access decision was then rated as either appropriate, uncertain or inappropriate. The results showed that 35% were considered appropriate, 28% were uncertain and 37% were deemed inappropriate.<\/p>\n\n\n\n
In haematological cancers such as acute leukaemia and aggressive lymphoma, according to MAGIC-ONC, the most appropriate vascular access options identified by MAGIC\u2011ONC are double\u2011lumen PICCs and double\u2011lumen tunnelled CVCs, as these patients require immediate treatment, often with vesicant or irritant drugs, alongside frequent blood product administration. Ports are considered \u2018inappropriate\u2019 in urgent situations because the procedure takes longer to arrange and early infection risk is higher in patients who are neutropenic or thrombocytopenic.<\/p>\n\n\n\n
For patients with indolent lymphoma and myeloma, MAGIC\u2011ONC identifies double\u2011lumen PICCs and tunnelled CVCs as appropriate for most treatment plans, while ports are suitable when vesicant therapy is required but not urgent. Midlines are generally considered \u2018inappropriate\u2019 in these settings as these patients often undergo multiple cycles of treatment, which increases the risk of venous depletion.<\/p>\n\n\n\n
For patients with solid tumours, MAGIC\u2011ONC identifies single\u2011lumen tunnelled CVCs and single\u2011lumen ports as the most appropriate options, and these remain suitable regardless of treatment intensity or duration. PICCs are considered \u2018appropriate\u2019 when treatment is urgent or expected to last fewer than three months, while triple\u2011lumen devices are viewed as \u2018inappropriate\u2019 because they carry a higher risk of infection and thrombosis.<\/p>\n\n\n\n
For specialised therapies, MAGIC\u2011ONC recommends specific devices based on flow and access requirements.<\/p>\n\n\n\n
To support vein preservation in patients with chronic kidney disease, MAGIC\u2011ONC recommends nephrology consultation for anyone with CKD stage 3B+ or higher and advises avoiding PICCs whenever possible.<\/p>\n\n\n\n
The guidance also outlines device choice based on expected duration of use:<\/p>\n\n\n\n
MAGIC\u2011ONC notes that patient preference for both the device type and insertion site is considered appropriate, and it highlights the right internal jugular vein as the preferred site for CVC placement.<\/p>\n\n\n\n
Internal jugular ports are favoured over subclavian ports to avoid the risk of pinch\u2011off syndrome, and for patients with head and neck cancer, chest ports are preferred to keep the device away from radiation fields. In the context of neutropenia, ports are rated as neutral, while all other vascular access devices are considered appropriate.<\/p>\n\n\n\n
The guidance also sets out thrombocytopenia thresholds to support safe insertion: PICCs and non-tunnelled CVCs may be placed at platelet counts of at least 10 \u00d710\u2079\/L, whereas tunnelled CVCs and ports require counts of at least 30 \u00d710\u2079\/L.<\/p>\n\n\n\n
MAGIC\u2011ONC advises that ports can be safely flushed at intervals of between four and twelve weeks, and it recommends the use of normal saline rather than heparin for routine maintenance. The guidance states that antimicrobial lock solutions such as ethanol, taurolidine and hydrochloric acid are \u2018inappropriate\u2019 for routine use, while citrate locking is considered \u2018neutral\u2019. Routine prophylactic antibiotics are not recommended for either insertion or ongoing maintenance. Devices should be removed if exit\u2011site or tunnel infections are present, and infectious diseases specialists should be consulted when continued access is required.<\/p>\n\n\n\n
MAGIC\u2011ONC also highlights several important considerations for thrombosis prevention and management, outlining which practices should be avoided and which are appropriate in high\u2011risk situations.<\/p>\n\n\n\n
MAGIC\u2011ONC highlights that vascular access choice is itself a modifiable risk factor for cancer patient outcomes.<\/p>\n\n\n\n
Its guidance supports:<\/p>\n\n\n\n
The authors also note strong potential for future quality metrics, such as appropriateness scoring, infection rates, thrombosis rates, and lumen\u2011number benchmarking.<\/p>\n\n\n\n
MAGIC-ONC provides a much\u2011needed framework to support safer and more consistent vascular access decisions for adults with cancer. By examining real clinical scenarios and identifying what is appropriate across different cancers, therapies and clinical circumstances, it gives teams a practical reference that can be applied at the bedside and across multidisciplinary services. Its guidance on device selection, insertion, maintenance and thrombosis management reinforces the importance of tailoring decisions to the individual patient while reducing unnecessary variation in practice.<\/p>\n\n\n\n
Together with the Association of Anaesthetists\u2019 Safe Vascular Access Guidelines, it offers clinicians a clearer pathway for improving safety, preventing complications and supporting better outcomes for patients who depend on reliable vascular access throughout their treatment.<\/p>\n\n\n\n
Chopra V, Swaminathan L, LeDonne J, Becker C, Krein SL, et al. Johnston AJ, Simpson MJ, McCormack V, Barton A, Bennett J, Chalisey A, et al. The landscape of vascular access is evolving rapidly, driven by new therapies, increasingly complex patient needs, and an ever\u2011stronger focus on safety and consistency. As clinicians strive to balance therapeutic effectiveness with minimising harm, high\u2011quality guidance becomes essential. At the end of 2025, two major publications answered that call: the Association of Anaesthetists\u2019 Safe Vascular […]<\/p>\n","protected":false},"author":141,"featured_media":52625,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[19],"tags":[],"class_list":["post-52624","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-vascular-access"],"acf":[],"_links":{"self":[{"href":"https:\/\/campusvygon.com\/uk\/wp-json\/wp\/v2\/posts\/52624","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/campusvygon.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/campusvygon.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/campusvygon.com\/uk\/wp-json\/wp\/v2\/users\/141"}],"replies":[{"embeddable":true,"href":"https:\/\/campusvygon.com\/uk\/wp-json\/wp\/v2\/comments?post=52624"}],"version-history":[{"count":1,"href":"https:\/\/campusvygon.com\/uk\/wp-json\/wp\/v2\/posts\/52624\/revisions"}],"predecessor-version":[{"id":52626,"href":"https:\/\/campusvygon.com\/uk\/wp-json\/wp\/v2\/posts\/52624\/revisions\/52626"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/campusvygon.com\/uk\/wp-json\/wp\/v2\/media\/52625"}],"wp:attachment":[{"href":"https:\/\/campusvygon.com\/uk\/wp-json\/wp\/v2\/media?parent=52624"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/campusvygon.com\/uk\/wp-json\/wp\/v2\/categories?post=52624"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/campusvygon.com\/uk\/wp-json\/wp\/v2\/tags?post=52624"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
The Michigan Appropriateness Guide for Intravenous Catheters in Adult Patients With Cancer (MAGIC\u2011ONC): Results from a multispecialty panel using the RAND\/UCLA Appropriateness Method.<\/em>
Ann Intern Med. 2025;178(Suppl 12):S1.<\/p>\n\n\n\n
Association of Anaesthetists guidelines: safe vascular access 2025.<\/em>
Anaesthesia. 2025;80(11):1381\u20131396. doi:10.1111\/anae.16727.<\/p>\n","protected":false},"excerpt":{"rendered":"